Biosimilars and Interchangeable Biologics: Strategic Elements - Image 1

£104.30

CRC Press Biosimilars and Interchangeable Biologics: Strategic Elements

Name: Biosimilars and Interchangeable Biologics: Strategic Elements
Brand: CRC Press
Price: 104.3 GBP
Availability: InStock

Accounting

This is the most expensive it has ever been. Walk away.

£104 today · previous high £104 · all-time low £28

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey

↓ Forecast
where the price is heading next

↓ Statistics
all-time high & low, recent range

↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 76 days · 76 data points (no recent data)

Historical

Generating forecast…

Price Distribution

Price distribution over 76 days • 3 price levels

Days at Price

Current Price

Price Analysis

Most common price: £42 (50 days, 65.8%)

Price range: £28 - £104

Price levels: 3 different prices over 76 days

Description

What’s the Deal with Biosimilars?Biosimilars are gaining momentum as new protein therapeutic candidates that can help fill a vital need in the healthcare industry. The biological drugs are produced by recombinant DNA technology that allows for large-scale production and an overall reduction time in costs and development. Part of a two-volume set that covers varying aspects of biosimilars, Biosimilars and Interchangeable Biologics: Strategic Elements explores the strategic planning side of biosimilar drugs and targets issues surrounding biosimilars that are linked to legal matters. This includes principal patents and intellectual property, regulatory pathways, and concerns about affordability on a global scale. It addresses the complexity of biosimilar products, and it discusses the utilization of biosimilars and related biological drugs in expanding world markets.Of specific interest to practitioners, researchers, and scientists in the biopharmaceutical industry, this volume examines the science, technology, finance, legality, ethics, and politics of biosimilar drugs. It considers strategic planning elements that include an overall understanding of the history and the current status of the art and science of biosimilars, and it provides detailed descriptions of the legal, regulatory, and commercial characteristics. The book also presents a global strategy on how to build, take to market, and manage the next generation of biosimilars throughout their life cycle. About the Author Sarfaraz K. Niazi, PhD, is the founding executive chairman of Therapeutic Proteins International LLC, a world-class pure-play developer and manufacturer of biosimilar and interchangeable recombinant biologics, headquartered in Chicago. Dr. Niazi began his career teaching pharmacy at the University of Illinois (1972–1988), where he became a tenured professor. He then entered the pharmaceutical industry at Abbott International, becoming a Volwiler Fellow. He left Abbott in 1995 with a passion for making high-cost biological drugs affordable. Dr. Niazi set up several ex-U.S. biosimilar companies and, in 2003, established Therapeutic Proteins International, the only U.S. integrated company of its kind to date.

Product Specifications

Brand: CRC Press
Format: paperback
ASIN: 1138775509
Category: Books > Subjects > Business, Finance & Law > Accounting
Domain: Amazon UK
Release Date: 26 July 2017
Listed Since: 26 January 2017

Barcode

No barcode data available

CRC Press Biosimilars and Interchangeable Biologics: Strategic Elements

This is the most expensive it has ever been. Walk away.

Price History & Forecast

Price Distribution

Price Analysis

Description

Product Specifications

Barcode

Similar Products You Might Like

Biosimilars and Interchangeable Biologics: Strategic Elements

Biosimilars and Interchangeable Biologics: Tactical Elements

Biosimilars and Interchangeable Biologics: Tactical Elements

Biosimilars Development Strategies: Fast to Market Approaches

Biologics and Biosimilars: Drug Discovery and Clinical Applications

Mastering Strategic Marketing For Specialty Pharmaceuticals: A Hands-on Guide

Biosimilar Clinical Development: Scientific Considerations and New Methodologies (Chapman & Hall/CRC Biostatistics Series)

The 2026-2031 World Outlook for High Potency APIs (HPAPIs)

Lipid-Based Nanocarriers for Drug Delivery and Diagnosis (Micro and Nano Technologies)

Integrated Pharmaceutics: Applied Preformulation, Product Design, and Regulatory Science

Economics of the Pharmaceutical and Medical Device Industry: Supply Chain, Trade and Innovation (Routledge Studies in the Economics of Innovation)

Commercialization of BioPharma Products in the USA (BW): A Practical Guide

Development of Therapeutic Agents Handbook: 8 (Pharmaceutical Development Series)

Process Chemistry in the Pharmaceutical Industry, Volume 2: Challenges in an Ever Changing Climate

Biosimilars: A New Generation of Biologics

Biosimilars: A New Generation of Biologics

Disposable Bioprocessing Systems

Boosting Pharmaceutical Innovation in the Post-TRIPS Era: Real-Life Lessons for the Developing World

Dorosz guide pratique des medicaments 2023, 42e ed

World Pharmaceutical Industry

Lipoxygenases in Inflammation (Progress in Inflammation Research)

Regulatory Protection in the Pharmaceutical and Life Science Industries: Challenges, Opportunities and Ongoing Reform (Elgar Monographs in Intellectual Property Law)

Digital Therapeutics: Strategic, Scientific, Developmental, and Regulatory Aspects (Chapman & Hall/CRC Biostatistics Series)

Analytical Similarity Assessment in Biosimilar Product Development